BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23342259)

  • 1. Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer.
    Khaja AS; Egevad L; Helczynski L; Wiklund P; Andersson T; Bjartell A
    Cancer Med; 2012 Aug; 1(1):96-104. PubMed ID: 23342259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome.
    Syed Khaja AS; Helczynski L; Edsjö A; Ehrnström R; Lindgren A; Ulmert D; Andersson T; Bjartell A
    PLoS One; 2011; 6(10):e26539. PubMed ID: 22039506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.
    Yamamoto H; Oue N; Sato A; Hasegawa Y; Yamamoto H; Matsubara A; Yasui W; Kikuchi A
    Oncogene; 2010 Apr; 29(14):2036-46. PubMed ID: 20101234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
    Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
    FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.
    Wang Q; Williamson M; Bott S; Brookman-Amissah N; Freeman A; Nariculam J; Hubank MJ; Ahmed A; Masters JR
    Oncogene; 2007 Oct; 26(45):6560-5. PubMed ID: 17486081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer biochemical recurrence rates after robotic-assisted laparoscopic radical prostatectomy.
    Ginzburg S; Nevers T; Staff I; Tortora J; Champagne A; Kesler SS; Laudone VP; Wagner JR
    JSLS; 2012; 16(3):443-50. PubMed ID: 23318071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
    Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy.
    Raatikainen S; Aaltomaa S; Palvimo JJ; Kärjä V; Soini Y
    Scand J Urol; 2015 Feb; 49(1):51-7. PubMed ID: 24779451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy.
    Bargão Santos P; Lobo J; Félix A; Silva F; Manso RT; Costa JO; Lourenço B; Sequeira JP; Jerónimo C; Patel HHR; Henrique R
    Urol Oncol; 2020 Oct; 38(10):794.e17-794.e27. PubMed ID: 32278731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule.
    Vau N; Henriques V; Cheng L; Blanca A; Fonseca J; Montironi R; Cimadamore A; Lopez-Beltran A
    Hum Pathol; 2019 Nov; 93():6-15. PubMed ID: 31442520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
    Lu J; Wirth GJ; Wu S; Chen J; Dahl DM; Olumi AF; Young RH; McDougal WS; Wu CL
    J Urol; 2012 Jul; 188(1):91-7. PubMed ID: 22578729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.